NewEdge Advisors’s Blueprint Medicines BPMC Stock Holding History

NewEdge Advisors’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-4	Closed	-$513	–	4114
2025 Q2	$513	Hold	4	–	–	﹤0.01%	3802
2025 Q1	$354	Hold	4	–	–	﹤0.01%	3754
2024 Q4	$349	Hold	4	–	–	﹤0.01%	3703
2024 Q3	$370	Hold	4	–	–	﹤0.01%	3636
2024 Q2	$431	Hold	4	–	–	﹤0.01%	3585
2024 Q1	$379	Hold	4	–	–	﹤0.01%	3611
2023 Q4	$369	Hold	4	–	–	﹤0.01%	3560
2023 Q3	$201	Hold	4	–	–	﹤0.01%	3326
2023 Q2	$253	Hold	4	–	–	﹤0.01%	3368
2023 Q1	$180	Hold	4	–	–	﹤0.01%	3316
2022 Q4	$0	Buy	+4	New	+$192	﹤0.01%	4095

Other funds holding BPMC

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

NewEdge Advisors's BPMC Position: Q3 2025 in Review

NewEdge Advisors sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 4 shares — an estimated $513 sold.

NewEdge Advisors first reported a position in BPMC in Q4 2022 and held it in 11 quarters. The position peaked at $513 in Q2 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

NewEdge Advisors reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
NewEdge Advisors sold 4 Blueprint Medicines shares in Q3 2025, an estimated $513.
NewEdge Advisors first reported a position in Blueprint Medicines in Q4 2022 and held it in 11 quarters.
NewEdge Advisors's Blueprint Medicines position peaked at $513 in Q2 2025.
5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on NewEdge Advisors's 13F filing for Q3 2025, filed 17 Nov 2025.